Endocrine therapy drugs are anti-hormone medications that used to help treat hormone-receptor positive breast cancer by blocking the body's natural hormones like estrogen and progesterone which promote tumor cell growth. These drugs have several advantages over other cancer treatments as they have shown fewer side effects compared to chemotherapy and are taken orally over a long period of time. The need for such effective drugs for treating hormone-dependent cancers is rising globally due to increasing cases of breast cancer.

The global Endocrine Therapy Drugs (ETDS) Market  is estimated to be valued at US$ 35060.96 Mn  in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The rising incidences of hormone-dependent cancers such as breast cancer especially in developed economies presents a major growth opportunity in the Endocrine Therapy Drugs (ETDS) Market . According to World Health Organization (WHO) data, breast cancer is estimated to account for nearly 12% of all new cancer cases globally and over 600,000 deaths are recorded each year. Effective treatment options using endocrine therapy drugs can help control tumor growth and improve survival rates significantly. Thus, the increasing demand for lowering cancer mortality and effective drugs for long term treatment of hormone-dependent cancers will continue driving the demand for endocrine therapy drugs over the forecast period.

Porter's Analysis
Threat of new entrants: Low since requires significant research and development investments, regulatory approvals and established customer relationships.
Bargaining power of buyers: Moderate since few buying options available and pricing trends established industry wide.
Bargaining power of suppliers: Moderate as well supply controlled few major players but rising generics market increasing supply side options.
Threat of new substitutes: Low as drugs proven safe and effective for treating hormone related cancers showing high patient compliance.
Competitive rivalry: High among large multinational brands offsetting patent expiries through portfolio expansion and targeted acquisitions.

SWOT Analysis
Strengths: Large R&D budgets, global footprint, established brands and expertise in oncology.
Weaknesses: Heavy dependence on few blockbuster drugs, patent cliffs and price erosion pressures. High costs of clinical trials.
Opportunities: Rising cancer incidence, scope for indications expansion, new combination therapies, biosimilars market growth.
Threats:regulatory hurdles, drug development failures, shifting treatment paradigm, changing reimbursement policies.

Key Takeaways
Global Endocrine Therapy Drugs (ETDS) Market Size is expected to witness high growth over the forecast period of 2024 to 2031 on account growing geriatric population and rising cancer prevalence globally. The global Endocrine Therapy Drugs (ETDS) Market  is estimated to be valued at US$ 35060.96 Mn  in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

By region, North America is expected dominate the market over the forecast period owing to high healthcare expenditure, favourable reimbursement schemes and presence of leading manufacturers. Europe is also expected grow at a significant pace backed by increasing initiatives for cancer research and awareness projects.

Key players operating in the Endocrine Therapy Drugs (ETDS) Market  are Johnson & Johnson, Procter & Gamble, Kimberly-Clark, Essity Aktiebolag, Kao Corporation, Daio Paper Corporation, Unicharm Corporation, Premier FMCG, Ontex, Hengan International Group Company Ltd., Drylock Technologies and Natracare LLC. The market is highly consolidated requiring continuous innovations to maintain edge over competition. Longer patent lives and strategic collaborations and M&A are some measures adopted by leading players to offset generic threats.

Explore More Related Article On This Topic: https://www.newsanalyticspro.com/the-endocrine-therapy-drugs-etds-market-is-driven-by-increasing-prevalence/

Explore More Related Article : https://www.timessquarereporter.com/business/the-global-training-market-growth-accelerated-by-leveraging-ai-and-analytics-technologies